Sweden’s lower HbA1c target values not linked to further organ protection
FDA’s approval of canagliflozin for slowing progression of diabetic nephropathy in patients with type 2 diabetes makes the drug the first new treatment option in nearly 20 years indicated for slowing diabetic kidney disease in these patients.
Continued monotherapy with metformin, compared with a sulfonylurea, is associated with a lower risk for major adverse cardiovascular events (MACE) among patients with type 2 diabetes who experienced reduced kidney function.
New review identifies benefits of sodium-glucose co-transporter-2 (SGLT2) inhibitors at almost all levels of kidney function.
Machine learning algorithms can aid in assessment of renal histopathology
The FDA has granted Fast Track designation to dapagliflozin (Farxiga; AstraZeneca) as a possible treatment to delay the progression of renal failure and prevent cardiovascular (CV) and renal death in patients with chronic kidney disease.
Testing for acid load needed in patients with diabetes taking sodium-glucose cotransporter-2 inhibitors
Studies document renal benefits of canagliflozin, dapagliflozin, empagliflozin, and dulaglutide
In a phase 2 study of patients with early diabetic nephropathy, esaxerenone decreased microalbuminuria in a dose-dependent manner over 12 weeks compared with placebo.
In the REWIND trial of type 2 diabetes patients, dulaglutide modestly reduced cardiovascular events and progression of kidney disease for at least 5 years.